BioCentury | Apr 14, 2020
Finance

Cerevance raises $45M toward series B, plans four more clinical programs for CNS disorders

With one CNS program in Phase II and four more approaching the clinic’s doorstep, Cerevance has raised the first $45 million of a series B round that could reach $60 million -- although the COVID-19...
BioCentury | Jun 23, 2018
Emerging Company Profile

Cerevance’s human element

Cerevance Inc. plans to treat neurological diseases by rebalancing disrupted neuronal circuits. The company is identifying circuit-specific neurological targets via its NETSeq RNA profiling platform, and thinks its ability to start with human tissue will...
Items per page:
1 - 2 of 2